Patients with BRAF V600E mutant metastatic colorectal cancer (mCRC) derive little benefit from standard therapies and have an extremely poor prognosis. Recent data has demonstrated that adding an anti-epidermal growth factor receptor (EGFR) agent to a BRAF inhibitor, with or without an MEK inhibitor, improves overall survival and response rates compared to irinotecan-based chemotherapy for these patients.
EMJ Oncology 8 [Supplement 3] . 2020
September 2020
In this issue
Latest articles
All articles![](https://www.emjreviews.com/wp-content/uploads/2024/04/Onc-Aparna-Parikh-Interview-940x564.png)
![](https://www.emjreviews.com/wp-content/uploads/2024/03/TN-1-1-940x564.png)
![](https://www.emjreviews.com/wp-content/uploads/2024/02/Eugena-Stamuli-thumbnail-940x564.jpg)
![](https://www.emjreviews.com/wp-content/uploads/2024/02/GSK-ONC-010-23-2-Thumbnail-940x564.png)